The Manufacturers Life Insurance Company Takes $93,000 Position in LifeMD, Inc. (NASDAQ:LFMD)

The Manufacturers Life Insurance Company bought a new position in shares of LifeMD, Inc. (NASDAQ:LFMD) in the second quarter, HoldingsChannel reports. The institutional investor bought 13,551 shares of the company’s stock, valued at approximately $93,000.

Other large investors have also made changes to their positions in the company. Quest Partners LLC acquired a new stake in LifeMD in the second quarter worth about $31,000. EntryPoint Capital LLC acquired a new stake in shares of LifeMD during the 1st quarter worth approximately $89,000. Los Angeles Capital Management LLC bought a new stake in shares of LifeMD during the second quarter worth approximately $88,000. XTX Topco Ltd acquired a new position in LifeMD in the second quarter valued at approximately $94,000. Finally, Virtu Financial LLC bought a new position in LifeMD in the first quarter valued at approximately $249,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Price Performance

LFMD opened at $4.68 on Monday. The stock has a market cap of $195.42 million, a P/E ratio of -6.32 and a beta of 1.18. LifeMD, Inc. has a 12 month low of $4.10 and a 12 month high of $12.88. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83. The company has a fifty day simple moving average of $5.04 and a 200 day simple moving average of $7.10.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $50.66 million during the quarter, compared to the consensus estimate of $48.47 million. During the same period in the prior year, the business earned ($0.23) EPS. On average, research analysts expect that LifeMD, Inc. will post -0.49 EPS for the current year.

Analyst Ratings Changes

Several brokerages have commented on LFMD. KeyCorp dropped their target price on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. B. Riley started coverage on LifeMD in a research note on Friday, August 23rd. They set a “buy” rating and a $11.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, LifeMD has an average rating of “Buy” and an average target price of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.